First analysis of gene therapy for RPE65 inherited retinal dystrophies shows good safety, efficacySeptember 3rd 2022
At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.
RGX-314 provided 2-Step or more improvement in diabetic severity in Phase 2 Altitude study analysisSeptember 2nd 2022
The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.
Hair cortisol may act as molecular biomarker for retinitis pigmentosa patientsSeptember 1st 2022
Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.
Fight Retinal Blindness! registry data: Ranibizumab and aflibercept safe for treating DMO over 3 yearsAugust 30th 2022
The investigators retrospectively analysed treatment-naive eyes with DMO which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected via Fight Retinal Blindness! registry.
EURETINA celebrates women in retinaAugust 28th 2022
The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.